ENLIVEN THERAPEUTICS INC (ELVN) — insider trading
Health Care · NASDAQ
ENLIVEN THERAPEUTICS INC (ELVN) has 86 reported SEC Form 4 insider transactions in our data, including 50 open-market sales among the most recent 86 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Garland J. Scott | Director | Option exercise / conversion (derivative) | 13,000 | — | $0 | Form 4 |
| 2026-10-01 | Garland J. Scott | Director | Open-market sale | 13,000 | $46.67 | $606.7K | Form 4 |
| 2026-10-01 | Garland J. Scott | Director | Option exercise / conversion | 13,000 | $15.47 | $201.1K | Form 4 |
| 2026-09-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 3,982 | — | $0 | Form 4 |
| 2026-09-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 289 | $51.49 | $14.9K | Form 4 |
| 2026-09-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 2,194 | $50.72 | $111.3K | Form 4 |
| 2026-09-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 3,535 | $50.03 | $176.9K | Form 4 |
| 2026-09-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 3,982 | $14.85 | $59.1K | Form 4 |
| 2026-09-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-09-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 240 | $51.48 | $12.4K | Form 4 |
| 2026-09-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,844 | $50.71 | $93.5K | Form 4 |
| 2026-09-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,916 | $50.03 | $145.9K | Form 4 |
| 2026-09-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-08-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-08-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,100 | $59.35 | $65.3K | Form 4 |
| 2026-08-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 3,900 | $58.37 | $227.6K | Form 4 |
| 2026-08-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-08-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,388 | $59.35 | $82.4K | Form 4 |
| 2026-08-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 4,630 | $58.35 | $270.2K | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion (derivative) | 20,491 | — | $0 | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion (derivative) | 23,364 | — | $0 | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion (derivative) | 27,567 | — | $0 | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion (derivative) | 87,373 | — | $0 | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Open-market sale | 158,795 | $60.21 | $9.56M | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion | 20,491 | $22.47 | $460.4K | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion | 23,364 | $14.85 | $347.0K | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion | 27,567 | $25.28 | $696.9K | Form 4 |
| 2026-08-04 | Derynck Mika K | Director | Option exercise / conversion | 87,373 | $2.48 | $216.7K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 63 | $53.92 | $3.4K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,184 | $53.42 | $116.7K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,063 | $52.39 | $108.1K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 459 | $51.55 | $23.7K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 231 | $50.05 | $11.6K | Form 4 |
| 2026-07-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 1,072 | — | $0 | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 123 | $53.87 | $6.6K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 2,638 | $53.38 | $140.8K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 2,564 | $52.32 | $134.1K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 369 | $51.48 | $19.0K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 324 | $49.97 | $16.2K | Form 4 |
| 2026-07-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 1,072 | $2.48 | $2.7K | Form 4 |
| 2026-07-06 | Kunkel Lori Anne | Director | Open-market sale | 5,889 | $50.84 | $299.4K | Form 4 |
| 2026-07-06 | Kunkel Lori Anne | Director | Open-market sale | 4,111 | $49.98 | $205.5K | Form 4 |
| 2026-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 46,776 | $45.00 | $2.10M | Form 4 |
| 2026-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 787,024 | $45.38 | $35.72M | Form 4 |
| 2026-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 1,477 | $45.00 | $66.5K | Form 4 |
| 2026-06-22 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 24,846 | $45.38 | $1.13M | Form 4 |
| 2026-06-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-06-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,133 | $44.74 | $50.7K | Form 4 |
| 2026-06-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,599 | $43.87 | $114.0K | Form 4 |
| 2026-06-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,268 | $42.83 | $54.3K | Form 4 |
| 2026-06-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-06-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion (derivative) | 6,018 | — | $0 | Form 4 |
| 2026-06-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,238 | $44.75 | $55.4K | Form 4 |
| 2026-06-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 3,401 | $43.86 | $149.2K | Form 4 |
| 2026-06-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 1,379 | $42.79 | $59.0K | Form 4 |
| 2026-06-17 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Option exercise / conversion | 6,018 | $2.48 | $14.9K | Form 4 |
| 2026-06-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 272,322 | $45.02 | $12.26M | Form 4 |
| 2026-06-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLC | 10% owner | Open-market sale | 9,086 | $45.02 | $409.1K | Form 4 |
| 2026-06-05 | Kunkel Lori Anne | Director | Open-market sale | 354 | $35.82 | $12.7K | Form 4 |
| 2026-06-05 | Kunkel Lori Anne | Director | Open-market sale | 1,867 | $35.36 | $66.0K | Form 4 |
| 2026-06-05 | Kunkel Lori Anne | Director | Open-market sale | 7,779 | $34.28 | $266.7K | Form 4 |
| 2026-05-18 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-05-18 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 223 | $41.21 | $9.2K | Form 4 |
| 2026-05-18 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 1,302 | $40.25 | $52.4K | Form 4 |
| 2026-05-18 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 3,475 | $39.53 | $137.4K | Form 4 |
| 2026-05-18 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-04-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-04-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,441 | $48.06 | $117.3K | Form 4 |
| 2026-04-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 2,419 | $47.39 | $114.6K | Form 4 |
| 2026-04-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 140 | $45.81 | $6.4K | Form 4 |
| 2026-04-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-03-25 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 40,000 | — | $0 | Form 4 |
| 2026-03-25 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 40,000 | $35.10 | $1.40M | Form 4 |
| 2026-03-25 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 40,000 | $2.48 | $99.2K | Form 4 |
| 2026-03-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 5,000 | — | $0 | Form 4 |
| 2026-03-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 5,000 | $27.76 | $138.8K | Form 4 |
| 2026-03-17 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 5,000 | $2.48 | $12.4K | Form 4 |
| 2026-03-10 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 10,129 | — | $0 | Form 4 |
| 2026-03-10 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 10,129 | $30.19 | $305.8K | Form 4 |
| 2026-03-10 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 10,129 | $2.48 | $25.1K | Form 4 |
| 2026-03-09 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 29,871 | — | $0 | Form 4 |
| 2026-03-09 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 29,871 | $30.02 | $896.8K | Form 4 |
| 2026-03-09 | Collins Helen Louise | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 29,871 | $2.48 | $74.1K | Form 4 |
| 2026-03-06 | Hohl Benjamin | Officer (CHIEF FINANCIAL OFFICER) | Open-market sale | 10,000 | $29.58 | $295.8K | Form 4 |
Ask the chat about ELVN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ENLIVEN THERAPEUTICS INC (ELVN).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.